Curis Inc (CRIS)vsRoyalty Pharma Plc (RPRX)
CRIS
Curis Inc
$0.47
-5.34%
HEALTHCARE · Cap: $19.49M
RPRX
Royalty Pharma Plc
$55.02
-1.09%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 34454% more annual revenue ($2.44B vs $7.06M). RPRX leads profitability with a 33.9% profit margin vs -299.7%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
CRIS
Avoid26
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-82.8%
Fair Value
$0.58
Current Price
$0.47
$0.11 premium
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -166.6% — below average capital efficiency
Revenue declined 66.0%
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CRIS
The strongest argument for CRIS centers on Price/Book, Debt/Equity.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : CRIS
The primary concerns for CRIS are EPS Growth, Market Cap, Return on Equity.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
CRIS profiles as a turnaround stock while RPRX is a mature play — different risk/reward profiles.
CRIS carries more volatility with a beta of 3.06 — expect wider price swings.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 26/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Curis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. The company is headquartered in Lexington, Massachusetts.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?